
Opinion|Videos|May 23, 2025
Important Patient and Clinical Considerations When Choosing Therapy in RRMM Following CAR T Therapy
Author(s)Aimaz Afrough, MD, Natalia Neparidze, MD
Panelists discuss how selinexor offers convenient oral administration, bispecific antibodies provide high response rates but may present toxicity risks, and cytotoxic chemotherapy is effective for aggressive disease but carries significant adverse effects and risks.
Advertisement
Episodes in this series

Physician Summary: Advantages and Disadvantages of Available Treatment Options
Selinexor:
- Advantages:
- Oral administration allows for easier access and reduces the need for frequent clinic visits.
- Convenient for patients who may prefer oral therapy over intravenous options.
- Disadvantages:
- Can have adverse effects like nausea and fatigue.
- May require dose adjustments based on tolerance.
Bispecific Antibodies:
- Advantages:
- High response rates in patients, offering effective disease control.
- Available as off-the-shelf therapies, providing rapid access.
- Disadvantages:
- Potential for toxicity, including cytokine release syndrome and neurotoxicity.
- Access limitations due to the need for specialized administration and possible cost issues.
- Infection risk due to immune modulation.
Cytotoxic Chemotherapy:
- Advantages:
- Effective for aggressive disease with quick action in cytoreduction.
- Broad applicability in various clinical settings.
- Disadvantages:
- Associated with myelosuppression, renal dysfunction, and the potential for hospitalization due to adverse effects.
- T-cell suppression, which can impair responses to subsequent immunotherapies.
Key Takeaway: Each treatment has its own benefit-risk profile—selinexor offers convenience, bispecific antibodies deliver high response rates, and cytotoxic chemotherapy can be effective in aggressive disease, though each carries specific challenges in terms of toxicity and patient burden.
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.

Alternating VR-CAP and rituximab plus cytarabine with continuous acalabrutinib produced deep responses and high MRD negativity in untreated MCL.

The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.

Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.

The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.

Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.

Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5

